Daily vitamin C may improve survival in people with precancerous blood disorders
A phase 2 trial found 1,000 mg of daily vitamin C meant fewer adverse events and a possible survival edge in people at risk of leukemia.
Summary
Vitamin C supplementation and blood cancer interception is the focus of a new phase 2 trial called EVITA. Researchers gave 109 people with precancerous blood conditions, such as clonal cytopenia of undetermined significance and early myelodysplastic disorders, either 1,000 mg of oral vitamin C daily or a placebo for one year. Those taking vitamin C had fewer adverse events and shifts in inflammatory signaling molecules linked to better outcomes. The supplement did not slow the expansion of abnormal blood cells. However, an exploratory analysis found that vitamin C recipients were significantly more likely to be alive after roughly three years. The investigators stress this survival signal is preliminary and must be confirmed in a larger phase 3 trial before anyone changes clinical practice. The work reflects a growing push toward cancer interception: acting before a cancer fully develops.
Detailed Summary
People with precancerous blood disorders often have persistently low vitamin C levels, and the risk of progressing to leukemia rises with age. That makes the question of whether correcting this deficiency can improve outcomes relevant to anyone interested in cancer prevention and healthy aging.
The phase 2 EVITA trial, run by the Van Andel Institute-Stand Up To Cancer Epigenetics Dream Team, was randomized, double-blind and placebo-controlled. It enrolled 109 patients with clonal cytopenia of undetermined significance or early-stage myelodysplastic disease. Participants took 1,000 mg of oral vitamin C or placebo daily for one year, and results appeared in the journal CANCER.
Vitamin C recipients had fewer adverse events during the study and follow-up. The supplement also shifted levels of certain cytokines, the immune signaling molecules, in patterns associated with more favorable outcomes. This suggests vitamin C may influence inflammation-related processes that drive the growth and progression of abnormal blood cells. It did not, however, significantly change the rate at which abnormal cell clones expanded. In an exploratory analysis, participants given vitamin C were significantly more likely to be alive after about three years of follow-up than those given placebo.
The researchers are now investigating how vitamin C interacts with precancerous cells, including the hypothesis that it helps restore normal epigenetic function in at-risk blood cells. This ties into the broader concept of cancer interception, which means intervening before malignancy is established.
For readers, the practical message is cautious. The authors themselves say it is too early for definitive recommendations. The survival result was exploratory, not a primary endpoint, and the sample was small. Anyone with a diagnosis of CCUS or myelodysplastic disease should talk with their hematologist before supplementing, since high-dose vitamin C can interact with treatments. A larger phase 3 trial will determine whether this simple, inexpensive intervention truly extends survival.
Key Findings
- Phase 2 EVITA trial randomized 109 patients with precancerous blood disorders to 1,000 mg daily vitamin C or placebo for one year.
- Vitamin C recipients experienced fewer adverse events during the study and follow-up period.
- Supplementation shifted cytokine levels in patterns linked to more favorable outcomes, hinting at anti-inflammatory effects.
- Vitamin C did not significantly slow expansion of abnormal blood cell clones.
- Exploratory analysis showed better survival at about three years; a phase 3 trial must confirm this.
Methodology
This is a university-sourced news summary of a randomized, double-blind, placebo-controlled phase 2 trial published in the peer-reviewed journal CANCER. Credibility is reasonably strong, but the article is a press release and the survival finding came from an exploratory analysis.
Study Limitations
The trial was small (109 patients), and the survival benefit was exploratory rather than a prespecified primary endpoint, so it may be a chance finding. The article is truncated and lacks effect sizes, confidence intervals and specifics on adverse events; consult the CANCER paper. Results may not apply to healthy people or to other vitamin C doses.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: